Zdroje

Plasma protein therapies replace missing or deficient proteins that allow individuals to lead healthy and more productive lives. The patients that rely on these therapies generally require regular infusions or injections throughout their lives. The diseases and conditions treated by plasma protein therapies are considered rare diseases because they affect a relatively small percent of the population. Most are genetic, chronic conditions.

Normal human immunoglobulins (IG) are used to treat patients with primary and secondary antibody deficiencies to supplement missing or malfunctioning antibodies and prevent occurrence of severe infections.

This report presents the case for expanding the availability of blood plasma for the production of plasma-derived medicinal products for patients in all European countries, by growing local donations of plasma.